Douglas Connect acts on its vision enabling discovery and innovation through openness and integration. In this spirit, DC provides an open implementation of the integrated testing strategy (ITS) that assesses skin sensitisation potency based on the previously described approach developed at Proctor and Gamble (Jaworska et al.). The DC ITS SKINSENS implementation combines information from three validated alternative assays (DPRA, KeratinoSens and h-CLAT) with in silico predictions for bioavailability using cheminformatics tools from the community.
DC ITS SKINSENS allows scientists to evaluate the skin sensitisation hazard of their chemicals using a combination of in vitro and in silico tools. It automatically compensates for the missing experimental data by using predicted values and utilizes the expert-knowledge embedded in the skin sensitization adverse outcome pathway (AOP) as published by OECD. DC ITS SKINSENS directs consequent testing and suggest the experiments to be conducted by value of information calculations to achieve maximum information gain and reduces uncertainty in prediction. The use of Bayesian networks allows tolerating missing information and conveys the probabilistic hypothesis of skin sensitization based on accumulative evidence from data.